葡萄糖-6-磷酸异构酶软骨寡聚基质蛋白抗突变型瓜氨酸波形蛋白抗体和抗环瓜氨酸肽抗体联合检测在类风湿关节炎诊断中的应用价值被引量：7

导出

摘要类风湿关节炎（rheumatoid arthritis，RA）是常见的以关节滑膜慢性炎症病变为主要表现的全身性自身免疫性疾病。目前诊断RA主要依靠临床症状和血清学诊断指标。近来发现葡萄糖-6-磷酸异构酶（GPI）及抗突变型瓜氨酸化波形蛋白（MCV）抗体与RA有一定相关性。软骨寡聚基质蛋白（COMP）也成为RA软骨病变早期诊断及评估软骨病变进展、预后及治疗效果的血清学指标。抗环瓜氨酸肽（CCP）抗体则对RA具有较高的特异度。

作者王亚强赵玉峰邢俊丽许培仁

机构地区河南大学淮河医院检验科

出处《中华风湿病学杂志》 CAS CSCD 北大核心 2010年第8期573-574,共2页 Chinese Journal of Rheumatology

基金河南省开封市科技发展计划（080325）

关键词葡萄糖-6-磷酸异构酶抗环瓜氨酸肽抗体软骨寡聚基质蛋白类风湿关节炎诊断指标抗突变型波形蛋白联合检测

分类号 R593.22 [医药卫生—内科学]

引文网络
相关文献

参考文献9

1Kamradt T,Schubert D.The role and clinical implications of G6PI in experimental models of rheumatoid arthritis.Arthritis Res Ther,2005,7:20-28.
2Schaller M,Stohl W,Tan SM,et al.Raised levels of anti-glucose-6-phosphate isomerase IgG in serum and synovial fluid from patients with inflammatory arthritis.Ann Rheum Dis,2005,64:743-749.
3Matsumoto I,Zhang H,Muraki Y,et al.A functional variant of Fc-gamma recep tor Ⅲ A is associated with rheumatoid arthritis in individuals who are positive for anti-glucose-6-phosphate isomerase antibodies.Arthritis Res Ther,2005,7:R1 183-R1 188.
4Muraki Y,Matsumoto I,Chino Y,et al.Glucose-6-phosphate isomerase variants play a key role in the generation of anti-GPIantibodies:possible mechanism of autoantibody production.Biochem Biophys Res Commun,2004,323:518-522.
5Nandakumar KS,Holmdahl R.Antibodyinduced arthritis:disease mechanisms and genes involved at the effector phase of arthritis.Arthritis Res Ther,2006,8:223.
6Matsumoto I,Muraki Y,Yasukochi T,et al.The exploration of joint specific immunoreactions on immunoglobulins G of antiglucose-6-phosphate isomerase antibody positive patients with rheumatoid arthritis.Int J Mol Med,2005,16:793-800.
7Hedbom E,Antonsson P,Hjerpe A,et al.Cartilage matrix proteins:an acidic oligomeric protein (COMP) detected only in cartilage.J Bio Chem,1992,267:6132-6136.
8吴敏,番解萍,马英淳.血清软骨寡聚基质蛋白检测在关节炎患者中的意义研究[J].中华风湿病学杂志,2008,12(8):534-536. 被引量：4
9Skoumal M,Kolarz G,Klingler A.Serum levels of cartilage oligomeric matrix protein:a predicting factor and avaluable parameter for disease management in rheumatoid arthritis.Scand J Rheumatol,2003,32:156-161.

二级参考文献8

1Hedbom E, Antonsson P, Hjerpe A, et al. Cartilage matrix proteins: an acidic oligomeric protein(COMP) detected only in cartilage. J Bio Chem, 1992, 267: 6132-6136.
2Van der Heijde D. How to read radiographs according to the Sharp/van der Heijde method. J Rheumatol, 2000, 27: 261-263.
3Skoumal M, Kolarz G, Klingler A. Serum levels of cartilage oligomeric matrix protein: a predicting factor and a valuable parameter for disease management in rheumatoid arthritis. Seand J Rheumatol, 2003, 32: 156-161.
4Crnkic M, Mansson B, Larsson L et al. Serum cartilage oligomeric matrix protein (COMP) decreases in rheumatoid arthritis patients treated with infliximab or etanercept. Arthritis Res Ther, 2003, 5: R181-185.
5Joosten LA, Helse MM, Saxne T, et al. IL-Ⅰ alpha beta blockade prevents cartilage and bone destruction in murine type Ⅱ collagen-induced arthritis, whereas TNF-α blockade only ameliorates joint inflammation. J Immunol, 1999, 163: 5049-5055.
6Kullich WC, Mur E, Aglas F, et al. Inhibitory effects of leflunomide therapy on the activity of matrixmetalloproteinase-9 and the release of cartilage oligomeric matrix protein in patients with rheumatoid arthritis. Clin Exp Rheumatol, 2006, 24: 155-160.
7Larsson E, Erlandsson-Harris H, Larsson A, et al. Corticosteroid treatment of experimental arthritis retards cartilage destruction as determined by histology and serum COMP. Rheumatol, 2004, 43: 428-434.
8Weitoft T, Larsson A, Saxne T, et al. Changes of cartilage and bone markers after intra-articular glucocorticoid treatment with and without postinjeetlon rest in patients with rheumatoid arthritis. Ann Rheum Dis, 2005, 64: 1750-1753.